GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Cancer Immunotherapy Clinical Trials

$1,168,320
Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Integrative Molecular Profiling of Human Pancreatic Cancer

$1,168,220
Syed Perwez Hussain · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Role of Immune and Inflammation Mediators in Progression of Pancreatic Cancer

$1,168,220
Syed Perwez Hussain · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Retroviral genetic modification of PBLs to optimize expansion for cell therapy

$1,166,802
Nicholas Klemen · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

TASK ORDER TITLE: EVALUATION OF REAL-TIME METABOLIC IMAGING BIOMARKERS FOR DETECTION OF PANCREATIC PREMALIGNANT LESIONS

$1,166,274
Powell Brown · University Of Tx Md Anderson Can Ctr · N01 · FY2021 · CA

Metal Chelate Conjugated Monoclonal Antibodies for Tumor Diagnosis and Therapy

$1,165,814
Martin W Brechbiel · Division Of Clinical Sciences - Nci · ZIA · FY2009 · CA

UCLA Center for Excellence in Pancreatic Diseases

$1,164,484
Vay Liang W. Go · University Of California Los Angeles · P01 · FY2007 · AT

Interacting Signaling Pathways that Initiate Squamous Cell Carcinogenesis

$1,163,016
Stuart H. Yuspa · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance

$1,162,978
Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R35 · FY2016 · CA

Center for digestive and liver diseases

$1,162,114
Anil K Rustgi · University Of Pennsylvania · P30 · FY2011 · DK

Targeting pancreatic cancer metastases with Targefrin

$1,162,000
Carlo Baggio · Armida Labs, Inc. · R44 · FY2025 · CA

Predicting Pancreatic Ductal Adenocarcinoma (PDAC) Through Artificial Intelligence Analysis of Pre-Diagnostic CT Images

$1,160,586
Debiao Li · Cedars-Sinai Medical Center · R01 · FY2021 · CA

Chemoprevention and mechanisms of obesity-promoted pancreatic adenocarcinoma

$1,159,739
Guido Erwin Michael Eibl · University Of California Los Angeles · P01 · FY2020 · CA

MOLECULAR BIOMARKERS

$1,158,819
Massachusetts Institute Of Technology · P01 · FY2000 · ES

A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy

$1,156,734
Amanda M Schalk · Enzyme By Design, Inc. · R44 · FY2020 · CA

Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

$1,155,055
Demetrius Albanes · Division Of Cancer Epidemiology And Genetics · ZIA · FY2009 · CA

Histidine phosphorylation as a new target for cancer therapy

$1,154,400
Tony R. Hunter · Salk Institute For Biological Studies · R35 · FY2025 · CA

Histidine phosphorylation as a new target for cancer therapy

$1,154,400
Tony R. Hunter · Salk Institute For Biological Studies · R35 · FY2020 · CA

Histidine phosphorylation as a new target for cancer therapy

$1,154,400
Tony R. Hunter · Salk Institute For Biological Studies · R35 · FY2022 · CA

Histidine phosphorylation as a new target for cancer therapy

$1,153,906
Tony R. Hunter · Salk Institute For Biological Studies · R35 · FY2021 · CA

Cellular In vivo Imaging

$1,153,574
Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Regulation of PDAC metabolism and immunity by collagen and its cleavage products

$1,152,768
Michael Karin · Sanford Burnham Prebys Medical Discovery Institute · U01 · FY2025 · CA

Strategies for Cancer Immunotherapy Clinical Trials

$1,151,937
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Pathways that Suppress or Accelerate Premalignant Progression of Squamous Cancer

$1,151,039
Stuart H. Yuspa · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Preclinical drug development in pancreatic cancer

$1,150,996
Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA